135,446 results match your criteria Rheumatoid Arthritis and Pregnancy


Taxifolin Inhibits Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis of Human Bone Marrow-Derived Macrophages in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo.

Pharmacology 2018 Dec 6;103(1-2):101-109. Epub 2018 Dec 6.

It has been reported that taxifolin inhibit osteoclastogenesis in RAW264.7 cells. In our research, the inhibition effects of taxifolin on the osteoclastogenesis of human bone marrow-derived macrophages (BMMs) induced by receptor activator of NF-κB ligand (RANKL) as well as the protection effects in lipopolysaccharide-induced bone lysis mouse model have been demonstrated. Read More

View Article
December 2018
3 Reads

Hide and Seek.

Surv Ophthalmol 2018 Dec 3. Epub 2018 Dec 3.

Wills Eye Hospital , Thomas Jefferson University, Philadelphia PA.

A 51-year-old woman with a previous history of rheumatoid arthritis experienced painless and progressive visual loss in the left eye for three weeks. Fundus examination revealed optic disc pallor in her left eye. Magnetic resonance imaging of the brain and orbits showed enhancement of the pachymeninges and hypersignal at the left optic nerve. Read More

View Article
December 2018
2 Reads

Expressway to Rheumatoid Arthritis by Macrophage-derived Microvesicle-Coated Nanoparticles.

Nano Lett 2018 Dec 6. Epub 2018 Dec 6.

The targeted delivery of therapeutics to sites of rheumatoid arthritis (RA) has been a long-standing challenge. Inspired by the intrinsic inflammation-targeting capacity of macrophages, macrophage-derived microvesicle (MMV)-coated nanoparticle (MNP) was developed for targeting RA. MMV was efficiently produced through a novel method. Read More

View Article
December 2018

Rheumatoid Arthritis and Mortality in End Stage Renal Disease.

J Clin Rheumatol 2018 Dec 5. Epub 2018 Dec 5.

Department of Medicine, Division of Rheumatology and Adult Allergy, Medical College of Georgia at Augusta University, Augusta, GA.

Objective: To determine whether rheumatoid arthritis (RA) is a risk factor for cardiovascular disease (CVD) events, all-cause mortality and cardiovascular mortality in End Stage Renal Disease (ESRD).

Methods: Cohort study of adult patients with ESRD in the United States Renal Data System (USRDS) with RA and a 5% random sample of those without RA. CVD events, all-cause mortality and cardiovascular mortality were determined in those with RA compared to those without RA using Cox Proportional Hazards modeling. Read More

View Article
December 2018

Recent-onset of rheumatoid arthritis leads to increase in wall thickness of left anterior descending coronary artery. An evidence of subclinical coronary artery disease.

Saudi Med J 2018 Dec;39(12):1213-1217

Ministry of Health and Prevention, Dubai, United Arab Emirates. E-mail.

Objectives: To explore the atherosclerotic changes of the left anterior descending coronary artery (LADCA) in patients with early onset of rheumatoid arthritis (RA).

Methods: Transthoracic echocardiographic scans were performed on 15 early RA patients and 20 control subjects, free of rheumatological diseases, diabetes mellitus (DM), and cardiovascular disease (CVD). Out of 15 RA patients, 10 were matched for age and gender with control. Read More

View Article
December 2018
0.554 Impact Factor

Anti-Parasitic Activity of Auranofin Against Pathogenic Naegleria fowleri.

J Eukaryot Microbiol 2018 Dec 5. Epub 2018 Dec 5.

Department of Veterinary Microbiology and Preventive Medicine, Ames, Iowa, 50011.

We report that the gold containing anti-rheumatoid drug auranofin is amoebicidal against human pathogenic Naegleria fowleri. Treatment of N. fowleri cultures at biologically relevant concentrations of 0. Read More

View Article
December 2018

The voice of patients in system redesign: A case study of redesigning a centralized system for intake of referrals from primary care to rheumatologists for patients with suspected rheumatoid arthritis.

Health Expect 2018 Dec 5. Epub 2018 Dec 5.

Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Background: The published literature demands examples of health-care systems designed with the active engagement of patients to explore the application of this complex phenomenon in practice.

Methods: This case study explored how the voice of patients was incorporated into the process of redesigning an element of the health-care system, a centralized system for intake of referrals from primary care to rheumatologists for patients with suspected rheumatoid arthritis (RA)-centralized intake. The phenomenon of patient engagement using "patient and community engagement researchers" (PaCERs) in research and the process of redesigning centralized intake were selected as the case. Read More

View Article
December 2018
1 Read

Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study.

Pharmgenomics Pers Med 2018 12;11:205-210. Epub 2018 Nov 12.

Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University and Flinders Medical Centre, Adelaide, SA, Australia.

Purpose: Methotrexate (MTX) treatment is associated with lower blood pressure (BP) and arterial stiffness in rheumatoid arthritis (RA). We investigated associations between single-nucleotide polymorphism (SNP) of the ATP-binding cassette efflux transporter gene (rs2231142), BP, and arterial stiffness in RA patients treated with MTX.

Patients And Methods: Clinical and 24-hour peripheral and central BP, arterial wave reflection (Augmentation Index, AIx), arterial stiffness (Pulse Wave Velocity, PWV), and intracellular MTX polyglutamate (MTXPGs) concentrations were assessed in 56 RA patients on stable treatment with MTX using a repeated cross-sectional study design with measurements at baseline and after 8 months. Read More

View Article
November 2018
1 Read

Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies.

Biologics 2018 12;12:151-158. Epub 2018 Nov 12.

Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.

Objectives: To describe the therapeutic pathways of patients with psoriasis (PSO) and psoriatic arthritis (PsA) before and after treatment with biological therapies in a real-world setting and to determine the relative consumption of health care resources.

Design: Retrospective observational study.

Setting: Real-life clinical setting in 5 Italian local health units. Read More

View Article
November 2018

Predicting Costs Exceeding Bundled Payment Targets for Total Joint Arthroplasty.

J Arthroplasty 2018 Nov 15. Epub 2018 Nov 15.

Department of Orthopaedics, Duke University Hospital, Duke Orthopaedics at Page Road, Durham, NC.

Background: The Center for Medicare and Medicaid Services has instituted bundled reimbursement models for total joint arthroplasty (TJA), which includes target prices for each procedure. Some patients exceed these targets; however, currently there are no tools to accurately predict this preoperatively. We hypothesized that a validated comorbidity index combined with patient demographics would adequately predict excess cost-of-care prior to hospitalization. Read More

View Article
November 2018

Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy.

Arthritis Res Ther 2018 Dec 5;20(1):268. Epub 2018 Dec 5.

Rheumatology and Immunology Center, China Medical University Hospital, No. 2, Yude Road, Taichung, 40447, Taiwan.

Background: Increasing evidence indicates a pathogenic role of deregulated autophagy in rheumatoid arthritis (RA). We examined the relationship between autophagy and inflammatory parameters in patients with RA receiving biologic therapy.

Methods: In 72 patients with RA and 20 healthy control subjects (HC), autophagosome levels were determined by the mean fluorescence intensity (MFI) of autophagosomotropic dye incorporated into circulating immune cells, and p62 expression levels in immune cells were measured by flow cytometry. Read More

View Article
December 2018
1 Read

A statistical measure for the skewness of X chromosome inactivation based on family trios.

BMC Genet 2018 Dec 5;19(1):109. Epub 2018 Dec 5.

State Key Laboratory of Organ Failure Research, Ministry of Education and Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China.

Background: X chromosome inactivation (XCI) is an important gene regulation mechanism in females to equalize the expression levels of X chromosome between two sexes. Generally, one of two X chromosomes in females is randomly chosen to be inactivated. Nonrandom XCI (XCI skewing) is also observed in females, which has been reported to play an important role in many X-linked diseases. Read More

View Article
December 2018
1 Read

Cannabinoid receptor 2 agonist prevents local and systemic inflammatory bone destruction in rheumatoid arthritis.

J Bone Miner Res 2018 Dec 3. Epub 2018 Dec 3.

Department of Orthopedics, The First Affiliated Hospital of Soochow University.

Cannabinoid receptor 2 (CB2) has been implicated as an important clinical regulator of inflammation and malignant osteolysis. Here, we observed that CB2 expression was markedly higher in the collagen-induced arthritis (CIA) mice synovium and bone tissues than in the non-inflamed synovium and bone tissues. The CB2 selective agonist (JWH133) but not antagonist (SR144528) suppressed CIA in mice without toxic effects, as demonstrated by the decreased synovial hyperplasia, inflammatory responses, cartilage damage, and periarticular and systemic bone destruction. Read More

View Article
December 2018

Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry.

Rheumatology (Oxford) 2018 Nov 30. Epub 2018 Nov 30.

Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.

Objective: To describe the outcomes of MTX and biologic DMARD (bDMARD) treatment in patients with RA and assess unmet needs in patients who fail treatment, using real-world data from the Norwegian DMARD (NOR-DMARD) registry.

Methods: Data included RA treatment courses from January 2007 until July 2016. Patients received MTX monotherapy (in MTX-naïve patients), bDMARD monotherapy, bDMARDs + MTX, or bDMARDs + other conventional synthetic DMARDs (csDMARDs). Read More

View Article
November 2018
2 Reads

Does the clinical phenotype of mucolipidosis-IIIγ differ from its αβ counterpart?: supporting facts in a cohort of 18 patients.

Clin Dysmorphol 2019 Jan;28(1):7-16

Greenwood Genetic Center, Greenwood, South Carolina.

Mucolipidosis-IIIγ (ML-IIIγ) is a recessively inherited slowly progressive skeletal dysplasia caused by mutations in GNPTG. We report the genetic and clinical findings in the largest cohort with ML-IIIγ so far: 18 affected individuals from 12 families including 12 patients from India, five from Turkey, and one from the USA. With consanguinity confirmed in eight of 12 families, molecular characterization showed that all affected patients had homozygous pathogenic GNPTG genotypes, underscoring the rarity of the disorder. Read More

View Article
January 2019

Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis.

Arthritis Rheumatol 2018 Dec 3. Epub 2018 Dec 3.

VA Nebraska-Western Iowa Health Care System, Omaha, NE, 68105.

Objective: To determine if the baseline presence of autoantibodies to peptidylarginine deiminase 4 (PAD4) predicts therapeutic response to biologic and conventional disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) who failed methotrexate (MTX) monotherapy.

Methods: Baseline serum from 282 RA patients who failed MTX monotherapy were screened for the presence of anti-PAD4 antibodies by immunoprecipitation. Clinical response to either triple DMARD (MTX, sulfasalazine, and hydroxychloroquine) or MTX-etanercept combination therapy was determined at 24- and 48-weeks post-treatment initiation. Read More

View Article
December 2018

The contribution of PTPN22 to rheumatological disease.

Arthritis Rheumatol 2018 Dec 3. Epub 2018 Dec 3.

Department of Medicine, University of California San Diego, 9500 Gilman Drive, MC0656, La Jolla, CA, 92093-0656.

One of the unresolved questions in modern medicine is why certain individuals develop a disorder such as rheumatoid arthritis or lupus, while others do not. Contemporary science holds genetics partly responsible and blames the remainder on environmental and stochastic factors. Among the many genes that increase the risk of autoimmune conditions, the risk allele encoding the W620 variant of PTPN22 is shared between multiple rheumatologic diseases, suggesting a fundamental role in the development of immune dysfunction. Read More

View Article
December 2018

Frequency of mental disorders among chronic pain patients with or without fibromyalgia in Japan.

Neuropsychopharmacol Rep 2018 Dec 11;38(4):167-174. Epub 2018 Aug 11.

Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan.

Aim: To explore the characteristics of psychiatric morbidity in chronic pain patients who present with or without fibromyalgia.

Methods: Patients are referred to our chronic pain clinic from primary medical institutions, as we are a secondary medical institution. Although some patients have chronic pain, they have no clear organic disorder such as rheumatoid arthritis to account for the pain. Read More

View Article
December 2018
3 Reads

Induction of Krüppel-like factor 2 reduces K/BxN serum-induced arthritis.

J Cell Mol Med 2018 Dec 3. Epub 2018 Dec 3.

Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas.

Krüppel-like factor 2 (KLF2) critically regulates activation and function of monocyte, which plays important pathogenic role in progressive joint destruction in rheumatoid arthritis (RA). It is yet to be established the molecular basis of KLF2-mediated regulation of monocytes in RA pathogenesis. Herein, we show that a class of compound, HDAC inhibitors (HDACi) induced KLF2 expression in monocytes both in vitro and in vivo. Read More

View Article
December 2018

Longitudinal Occurrence and Predictors of Patient-Provider Discordance Between Global Assessments of Disease Activity in Rheumatoid Arthritis: A Case-Control Study.

Arthritis Care Res (Hoboken) 2018 Nov 30. Epub 2018 Nov 30.

Division of Rheumatology.

Objective: The objective was to identify longitudinal predictors of discordance between patients with rheumatoid arthritis (RA) and their health care providers, where patient global assessment of disease activity is substantially higher than provider global assessment.

Methods: This retrospective case-control study included 102 cases with positive discordance (ie, ≥25 mm between patient and provider global assessments) and 102 controls without discordance who were matched for age, sex, RA duration, and Clinical Disease Activity Index (CDAI). Data were collected at the baseline visit (date of diagnosis or earliest available visit), the index visit (participation in a previous cross-sectional study), and at up to 11 additional visits before the index visit. Read More

View Article
November 2018

Association between activity and genotypes of paraoxonase1 LM (rs854560) increases the disease activity of rheumatoid arthritis through oxidative stress.

Mol Biol Rep 2018 Dec 1. Epub 2018 Dec 1.

Department of Microbiology, Immunology and Biochemistry, University of Tennessee, Health Science Center, Memphis, TN, USA.

Rheumatoid arthritis (RA) is considered as a long-term autoimmune disorder. Gene polymorphism and oxidative stress might be involved in the pathogenesis of the disease. We aimed to determine the association between PON-1L55M polymorphism and its effects on inflammatory markers such as anti-cytroline circulated-peptide (CCP)-antibodies, C-reactive protein (CRP), neopterin serum concentration, arylesterase (ARE) and butyrylcholinesterase (BuChE) activities and total-antioxidant-capacity (TAC) level with the activity of disease in RA patients. Read More

View Article
December 2018

Evaluation of cytokine profiles in rheumatoid arthritis patients with clinically active disease and normal inflammatory indices.

Clin Rheumatol 2018 Dec 1. Epub 2018 Dec 1.

Medstar Georgetown University Hospital, Washington, DC, USA.

Objective: To assess the potential utility of a cytokine measurement in rheumatoid arthritis (RA) patients with active joint disease but normal acute phase reactants (APR).

Methods: RA patients in a longitudinal observational registry with available cytokine array data were included. Patients were categorized based on agreement/disagreement of physical examination and APR measurements: concordant high (CH) [high tender and/or swollen joint counts (TJC + SJC > 3) and APR (ESR ≥ 28 mm/h + CRP ≥ 1. Read More

View Article
December 2018

A TRAF6 genetic variant is associated with low bone mineral density in rheumatoid arthritis.

Clin Rheumatol 2018 Dec 1. Epub 2018 Dec 1.

Laboratory of Immunology, Research Unit UR 807, Faculty of Medicine of Sousse, Ibn Al Jazzar street, 4000, Sousse, Tunisia.

Objectives: This study was aimed to investigate the association of the single nucleotide polymorphism of tumor necrosis factor receptor associated factor 6 (TRAF6), rs540386, with low bone mineral density (BMD) among patients with rheumatoid arthritis (RA).

Methods: TRAF6 rs540386 genotyping was performed by mutagenically separated PCR in a cohort of 188 (23 men, 165 women, median age, 56.2 years) adult RA patients and 224 age and gender-matched controls. Read More

View Article
December 2018

Intravenous anesthetic ketamine attenuates complete Freund's adjuvant-induced arthritis in rats via modulation of MAPKs/NF-κB.

Inflamm Res 2018 Nov 30. Epub 2018 Nov 30.

Department of Anesthesiology, The Second Xiangya Hospital, Central South University, 139 Ren-Min Road, Changsha, 410011, China.

Background: The current study was intended to investigate the effect of ketamine (KET) on complete Freund's adjuvant (CFA)-induced arthritis in rats.

Methods: The CFA was administered in the hind paw of the rats for the induction of adjuvant-induced arthritis. The paw swelling of experimental animals was measured as hind paw volume. Read More

View Article
November 2018

DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway.

Inflammation 2018 Dec 1. Epub 2018 Dec 1.

School of Stomatology, Dalian Medical University, Dalian, 116044, People's Republic of China.

Macrophages play a fundamental role in human chronic diseases such as rheumatoid arthritis, atherosclerosis, and cancer. In the present study, we demonstrated that dual-specificity phosphatase 6 (DUSP6) was upregulated by lipopolysaccharide (LPS) treatment of macrophages. (E/Z)-BCI hydrochloride (BCI) functions as a small molecule inhibitor of DUSP6, and BCI treatment inhibited DUSP6 expression in LPS-activated macrophages. Read More

View Article
December 2018

Interstitial lung disease associated with anti-citrullinated peptide/protein antibody-positive anti-synthetase syndrome.

J Thorac Dis 2018 Oct;10(10):5924-5931

Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanazawa-ku, Yokohama 236-0051, Japan.

Little has been reported on the characteristics of interstitial lung disease (ILD) associated with anti-citrullinated peptide/protein antibody (ACPA)-positive anti-synthetase syndrome (ASS). We sought to investigate the clinical, radiologic, and pathologic features of patients with ILD associated with ACPA-positive ASS. Medical records of seven ILD patients with positive results of both ACPA and anti-aminoacyl-tRNA synthetase antibody were retrospectively reviewed. Read More

View Article
October 2018
1 Read

Association Between rs7574865 Polymorphism and Rheumatoid Arthritis: Debate Unresolved.

Open Rheumatol J 2018 24;12:172-178. Epub 2018 Oct 24.

Department of Biochemistry and Microbiology, Faculty of Pharmacy, Damascus University, Damascus, Syria.

Background: rs7574865 polymorphism has been evidently associated with susceptibility to Rheumatoid Arthritis (RA) in European and Eastern Asian populations, whereas studies in other countries reported otherwise.

Objective: We investigated the distribution of rs7574865 polymorphism in a group of Syrian RA patients.

Methods: Eighty-one RA patients and forty healthy controls were enrolled and rs7574865 was genotyped by direct sequencing. Read More

View Article
October 2018
1 Read

Minimum Infliximab Dosage for Keeping Serum Infliximab Levels Greater than 1 µg/mL among Patients with Rheumatoid Arthritis.

Biol Pharm Bull 2018 ;41(12):1745-1747

Department of Orthopaedic Surgery, Meiji University of Integrative Medicine.

Infliximab shows drastic efficacy for controlling inflammation in rheumatoid arthritis (RA), though the ideal dose of infliximab to keep suppressing inflammation has not yet been identified. Recently, it has been evidenced that the minimum trough serum infliximab levels required for suppressing inflammation are greater than 1 µg/mL. This cross-sectional study was designed to identify the minimum dosage of infliximab for maintaining serum infliximab levels greater than 1 µg/mL. Read More

View Article
January 2018

Cost-effective Tapering Algorithm in Rheumatoid Arthritis Patients: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.

J Rheumatol 2018 Dec 1. Epub 2018 Dec 1.

From the Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Department of Internal Medicine 3 - Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany; St. Vincent Hospital, Vinforce Study Group, Medical University of Vienna, Vienna, Austria; Institutio de Rheumatologia, São Paolo, Brazil; University of Würzburg, Internal Medicine 2, Würzburg; University Medical Center Freiburg, Rheumatology and Clinical Immunology, Freiburg; Rheumatology Clinical Practice Erlangen, Erlangen; Rheumatology Practice and Department of Internal Medicine 2, Clinic Burghausen, Burghausen; Asklepios Medical Center, Department of Rheumatology and clinical Immunology, Bad Abbach; Rheumatology Practice Bamberg, Bamberg; Rheumatology Practice Bayreuth, Bayreuth; University of Heidelberg, Medicine 5, Heidelberg; Rheumatology Practice Nuremberg, Nuremberg; Schlosspark Klinik, Internal Medicine/Rheumatology, Berlin; University of Tübingen, Centre for Interdisciplinary Clinical Immunology, Tübingen; Praxiszentrum St. Bonifatius, Munich, Germany. M. Hagen, BSc, CandMed, FAU, Department of Internal Medicine 3 - Rheumatology and Immunology, Universitätsklinikum Erlangen; M. Englbrecht, PhD, FAU, Department of Internal Medicine 3 - Rheumatology and Immunology, Universitätsklinikum Erlangen; J. Haschka, MD, St. Vincent Hospital, Vinforce Study Group, Medical University of Vienna; M. Reiser, FAU, Department of Internal Medicine 3 - Rheumatology and Immunology, Universitätsklinikum Erlangen; A. Kleyer, MD, FAU, Department of Internal Medicine 3 - Rheumatology and Immunology, Universitätsklinikum Erlangen; A. Hueber, MD, FAU, Department of Internal Medicine 3 - Rheumatology and Immunology, Universitätsklinikum Erlangen; B. Manger, MD, FAU, Department of Internal Medicine 3 - Rheumatology and Immunology, Universitätsklinikum Erlangen; C. Figueiredo, MD, Institutio de Rheumatologia; J. Fogagnolo Cobra, MD, Institutio de Rheumatologia; H.P. Tony, MD, University of Würzburg, Internal Medicine 2; S. Finzel, MD, University Medical Center Freiburg, Rheumatology and Clinical Immunology; S. Kleinert, MD, Rheumatology Clinical Practice Erlangen; J. Wendler, MD, Rheumatology Clinical Practice Erlangen; F. Schuch, MD, Rheumatology Clinical Practice Erlangen; M. Ronneberger, MD, Rheumatology Clinical Practice Erlangen; M. Feuchtenberger, MD, Rheumatology Practice and Department of Internal Medicine 2, Clinic Burghausen; M. Fleck, MD, Asklepios Medical Center, Department of Rheumatology and clinical Immunology; K. Manger, MD, Rheumatology Practice Bamberg; W. Ochs, MD, Rheumatology Practice Bayreuth; H.M. Lorenz, MD, University of Heidelberg, Medicine 5; H. Nüsslein, MD, Rheumatology Practice Nuremberg; R. Alten, MD, Schlosspark Klinik, Internal Medicine/Rheumatology; J. Henes, MD, University of Tübingen, Centre for Interdisciplinary Clinical Immunology; K. Krüger, MD, Praxiszentrum St. Bonifatius; G. Schett, MD, FAU, Department of Internal Medicine 3 - Rheumatology and Immunology, Universitätsklinikum Erlangen; J. Rech, MD, FAU, Department of Internal Medicine 3 - Rheumatology and Immunology, Universitätsklinikum Erlangen. Address correspondence to Dr. J. Rech, Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine 3 - Rheumatology and Immunology, Universitätsklinikum Erlangen, Ulmenweg 18, 91054 Erlangen, Germany. E-mail: Accepted for publication September 7, 2018.

Objective: To analyze the effect of a risk-stratified disease-modifying antirheumatic drug (DMARD)-tapering algorithm based on multibiomarker disease activity (MBDA) score and anticitrullinated protein antibodies (ACPA) on direct treatment costs for patients with rheumatoid arthritis (RA) in sustained remission.

Methods: The study was a posthoc retrospective analysis of direct treatment costs for 146 patients with RA in sustained remission tapering and stopping DMARD treatment, in the prospective randomized RETRO study. MBDA scores and ACPA status were determined in baseline samples of patients continuing DMARD (arm 1), tapering their dose by 50% (arm 2), or stopping after tapering (arm 3). Read More

View Article
December 2018
2 Reads

Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid Arthritis.

J Rheumatol 2018 Dec 1. Epub 2018 Dec 1.

From the Sunnybrook Research Institute, Holland Bone and Joint Research Program, Toronto, Ontario; McGill University, Department of Epidemiology, Biostatistics and Occupational Health; Research Institute of the McGill University Health Centre, Department of Clinical Epidemiology, and Centre for Outcomes Research and Evaluation, Montreal, Quebec; ICES; University of Toronto, Institute of Health Policy, Management and Evaluation, Toronto; McMaster University, Department of Family Medicine, Hamilton; Southlake Regional Health Centre, Department of Medicine, Newmarket; Western University, Department of Epidemiology and Biostatistics; St. Joseph's Health Care, Department of Medicine, London; Mount Sinai Hospital, Department of Medicine, Toronto, Ontario, Canada. This analysis was supported by the Canadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research, which is funded by the Canadian Institutes of Health Research Drug Safety and Effectiveness Network (funding reference no. TD3-137716). JW was supported by fellowship awards from The Arthritis Society and the Canadian Institutes of Health Research (Banting) during the course of this work; SB holds a career award from the Fonds de la recherche en santé du Québec; MA is a James McGill Professor of Biostatistics at McGill University. This study was supported by the ICES, a nonprofit research corporation funded by the Ontario Ministry of Health and Long-Term Care. Parts of this material are based on data and/or information compiled and provided by the Canadian Institutes of Health Information (CIHI). However, the analyses, conclusions, opinions, and statements expressed in the material are those of the authors and not necessarily those of CIHI. J. Widdifield, PhD, Sunnybrook Research Institute, Holland Bone and Joint Research Program, and McGill University, Department of Epidemiology, Biostatistics and Occupational Health, and Research Institute of the McGill University Health Centre, Department of Clinical Epidemiology, ICES, and University of Toronto, Institute of Health Policy, Management and Evaluation; M. Abrahamowicz, PhD, McGill University, Department of Epidemiology, Biostatistics and Occupational Health, and Research Institute of the McGill University Health Centre, Centre for Outcomes Research and Evaluation; J.M. Paterson, MSc, ICES, and University of Toronto, Institute of Health Policy, Management and Evaluation, and McMaster University, Department of Family Medicine; A. Huang, MSc, ICES; J.C. Thorne, MD, FRCPC, Southlake Regional Health Centre, Department of Medicine; J.E. Pope, MD, FRCPC, MPH, Western University, Department of Epidemiology and Biostatistics, and St. Joseph's Health Care, Department of Medicine; B. Kuriya, MD, FRCPC, SM, Mount Sinai Hospital, Department of Medicine; M.E. Beauchamp, PhD, Research Institute of the McGill University Health Centre, Centre for Outcomes Research and Evaluation; S. Bernatsky, MD, FRCPC, PhD, McGill University, Department of Epidemiology, Biostatistics and Occupational Health, and Research Institute of the McGill University Health Centre, Centre for Outcomes Research and Evaluation. Address correspondence J. Widdifield, Holland Bone and Joint Research Program, Sunnybrook Research Institute MG 352, 2075 Bayview Ave., Toronto, Ontario M4N 3M5, Canada. E-mail: Accepted for publication August 22, 2018.

Objective: We evaluated the associations between time-varying methotrexate (MTX) use and risk of cardiovascular events (CVE) in patients with rheumatoid arthritis (RA).

Methods: We studied an inception cohort of 23,994 patients with RA diagnosed after their 65th birthday. Multivariable Cox regression models were fit to evaluate the associations between time-varying MTX use, controlling for other risk factors, and time to CVE. Read More

View Article
December 2018

Smoking Is Associated with Higher Disease Activity in Rheumatoid Arthritis: A Longitudinal Study Controlling for Time-varying Covariates.

J Rheumatol 2018 Dec 1. Epub 2018 Dec 1.

From the Division of Rheumatology, Department of Medicine, University of California, San Francisco, California, USA. This work was supported by the US National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH; grant number F32 AR070585 to MG and K23 AR063770 to GS) and the Agency for Healthcare Research and Quality (grant number R01 HS024412 to JY). Drs. Graf, Yazdany, and Schmajuk are also supported by the Russell/Engleman Medical Research Center for Arthritis. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality or the NIH. M.A. Gianfrancesco, PhD, MPH, Division of Rheumatology, Department of Medicine, University of California, San Francisco; L. Trupin, MPH, Division of Rheumatology, Department of Medicine, University of California, San Francisco; S. Shiboski, PhD, Department of Epidemiology and Biostatistics, University of California, San Francisco; M. van der Laan, PhD, Division of Biostatistics, School of Public Health, University of California, Berkeley; J. Graf, MD, Division of Rheumatology, Department of Medicine, University of California, San Francisco; J. Imboden, MD, Division of Rheumatology, Department of Medicine, University of California, San Francisco; J. Yazdany, MD, MPH, Division of Rheumatology, Department of Medicine, University of California, San Francisco; G. Schmajuk, MD, MS, Division of Rheumatology, Department of Medicine, University of California, San Francisco, and Veterans Affairs Medical Center, San Francisco, California, USA. Address correspondence to Dr. M.A. Gianfrancesco, Division of Rheumatology, Department of Medicine, University of California, San Francisco; 513 Parnassus Ave., San Francisco, California 94143, USA. E-mail: Accepted for publication August 10, 2018.

Objective: Prior studies around the relationship between smoking and rheumatoid arthritis (RA) disease activity have reported inconsistent findings, which may be ascribed to heterogeneous study designs or biases in statistical analyses. We examined the association between smoking and RA outcomes using statistical methods that account for time-varying confounding and loss to followup.

Methods: We included 282 individuals with an RA diagnosis using electronic health record data collected at a public hospital between 2013 and 2017. Read More

View Article
December 2018

Inflammation and Heart Rate-corrected QT Interval: Evidence for a Potentially Reversible Cause of Sudden Death in Patients with Rheumatoid Arthritis?

Authors:
Ahmed M Adlan

J Rheumatol 2018 Dec;45(12):1609-1610

Department of Cardiology, Liverpool Heart and Chest Hospital, Liverpool L14 3PE, UK.

View Article
December 2018

Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study.

Ann Rheum Dis 2018 Dec 1. Epub 2018 Dec 1.

Department of Clinical immunology and Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centre, Amsterdam, The Netherlands

Objectives: We explored the effects of B-cell directed therapy in subjects at risk of developing autoantibodypositive rheumatoid arthritis (RA), who never experienced inflammatory arthritis before, and explored biomarkers predictive of arthritis development.

Methods: Individuals positive for both anti-citrullinated peptide antibodies and rheumatoid factor but without arthritis were included in a randomised, double-blind, placebo-controlled study to receive a single infusion of 1000 mg rituximab or placebo.

Results: Eighty-one individuals received treatment and were followed up for a mean of 29. Read More

View Article
December 2018
1 Read

Combined synovectomy and extensor carpi radialis longus transfer to realign and stabilise the rheumatoid wrist.

Orthop Traumatol Surg Res 2018 Nov 29. Epub 2018 Nov 29.

Faculté de médecine de Tours, service d'orthopédie traumatologie, université François-Rabelais de Tours, CHRU de Trousseau, 1C, avenue de la République, 37170 Chambray-les-Tours, France.

Background: In patients with rheumatoid arthritis, the surgical treatment of wrist lesions relies on synovectomy combined with stabilisation and realignment of the carpal bones. The objective of this study was to evaluate the outcomes and define the indications of extensor carpi radialis longus (ECRL) transfer to the extensor carpi ulnaris (ECU) as described by Clayton and Ferlic.

Hypothesis: ECRL-to-ECU transfer combined with synovectomy can prevent the development and/or progression of rheumatoid deformities at the wrist. Read More

View Article
November 2018

Vascular endothelial growth factor signaling in VE-cadherin expression and tube-like formation by rheumatoid arthritic synovial fibroblast-like cells.

Biochem Biophys Res Commun 2018 Nov 28. Epub 2018 Nov 28.

Department of Biochemistry, The Nippon Dental University School of Life Dentistry at Tokyo, 1-9-20 Fujimi, Chiyoda-ku, Tokyo, 102-8159, Japan. Electronic address:

An increase in the vasculature is one of most representative changes in the synovial tissue of joints in rheumatoid arthritis (RA) and is closely associated with disease progression. Although the vasculatures are believed to be a result of VE-cadherin-dependent angiogenesis and a possible therapeutic target of the disease, synovial fibroblastic cells express VE-cadherin and form tube-like structures, suggesting that vasculatures in RA synovium may not simply result from angiogenesis. This paper analyzes a mechanism of VE-cadherin expression by rheumatoid arthritic synovial fibroblast-like cells (RSFLs) and their involvement in the tube-like formation. Read More

View Article
November 2018

The impact of the reverse prosthesis on revision shoulder arthroplasty: analysis of a high-volume shoulder practice.

J Shoulder Elbow Surg 2018 Nov 28. Epub 2018 Nov 28.

Shoulder Service, Department of Orthopedic Surgery, Massachusetts General Hospital, Boston Shoulder Institute, Boston, MA, USA. Electronic address:

Background: Since the approval of reverse shoulder arthroplasty (RSA) in 2004, the use of shoulder arthroplasty increased dramatically. Although the success of RSA in the revision setting has been demonstrated, there remains a paucity of studies examining the epidemiology of RSA in revision arthroplasty. This study describes trends of revision arthroplasty during the "era of the reverse," from 2005 through 2016. Read More

View Article
November 2018

Dyrk1A promotes the proliferation, migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis via down-regulating Spry2 and activating the ERK MAPK pathway.

Tissue Cell 2018 Dec 28;55:63-70. Epub 2018 Oct 28.

Department of Orthopedic, The Second Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, 226001, China. Electronic address:

Fibroblast-like synoviocytes (FLSs) play an essential role in rheumatoid arthritis (RA) by promoting synovitis, pannus growth and cartilage/bone destruction. Increased proliferation, migration and invasion of FLSs greatly contribute to RA initiation and progression. Dual-specificity tyrosine-regulated kinase 1A (Dyrk1A), a serine/threonine kinase, regulates MAPK pathway activation, and governs the proliferation and differentiation of neuronal progenitor cells and cancer cells. Read More

View Article
December 2018

Gene microarray analysis of expression profiles in Suberoyllanilide hyroxamic acid-treated Dendritic cells.

Biochem Biophys Res Commun 2018 Nov 27. Epub 2018 Nov 27.

Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, China. Electronic address:

Objective: The purpose of this study is to provide a further theoretical basis for the role of Suberoyllanilide hyroxamic acid (SAHA) affect on Dendritic cells (DCs).

Methods: We first downloaded the GSE74306 microarray data, which was about the effect of SAHA act on DCs, from the Gene Expression Omnibus database. Then we analyzed the differential expression genes (DEGs) between SAHA-treated DCs and SAHA-untreated DCs by limma package of R software; The Database for Annotation, Visualization and Integrated Discovery was used to analyze the Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways for these DEGs. Read More

View Article
November 2018

Cavitary pulmonary nodules in rheumatoid arthritis; case reports and review of the literature.

Eur J Rheumatol 2018 Mar;5(1):65-68

Department of Chest Disease, Yedikule Chest Diseases Training and Research Hospital, İstanbul, Turkey.

Rheumatoid nodules are the most common pulmonary manifestations of rheumatoid arthritis (RA) and are usually asymptomatic. In rare cases, they progress cavitary formation and cause severe clinical symptoms because of disease activity, infectious diseases, and other etiologies. The determination of clinical and histopathological features may be helpful for differential diagnosis in patients with RA with cavitary pulmonary nodules. Read More

View Article
March 2018
1 Read

Expression Analysis of Matrix Metalloproteinase-9 Gene in Rheumatoid Arthritis Patients on Disease Modifying Anti-Rheumatic Drugs.

J Coll Physicians Surg Pak 2018 Dec;28(12):902-905

Department of Pathology, Army Medical College, Rawalpindi, Pakistan.

Objective: To evaluate matrix metalloproteinase-9 gene expression in rheumatoid arthritis patients on disease modifying anti-rheumatic agents with the objective to further modify the current treatment regimen if indicated in order to prevent progression to deforming rheumatoid arthritis.

Study Design: Cross-sectional comparative study.

Place And Duration Of Study: CREAM Lab (Centre for Research in Experimental and Applied Medicine) and Department of Biochemistry and Molecular Biology, Army Medical College, in collaboration with Rheumatology Department at Military Hospital Rawalpindi from November 2015 to November 2016. Read More

View Article
December 2018

Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews.

Health Technol Assess 2018 Nov;22(66):1-294

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK.

Background: Rheumatoid arthritis (RA) is a chronic, debilitating disease associated with reduced quality of life and substantial costs. It is unclear which tests and assessment tools allow the best assessment of prognosis in people with early RA and whether or not variables predict the response of patients to different drug treatments.

Objective: To systematically review evidence on the use of selected tests and assessment tools in patients with early RA (1) in the evaluation of a prognosis (review 1) and (2) as predictive markers of treatment response (review 2). Read More

View Article
November 2018

[Autoimmune diseases in dogs and their impact for breeding programs with special reference of the Nova Scotia Duck Tolling Retriever].

Authors:
F Ehrensperger

Schweiz Arch Tierheilkd 2018 Dec;160(12):711-717

Institut für Veterinärpathologie, Vetsuisse-Fakultät, Universität Zürich.

Introduction: Autoimmune diseases are of considerable importance in dog breeding. An increased risk of diseases with genetic predisposition is present especially in breeds with a limited genetic diversity. Strict breeding regulations and a high degree of self responsibility of the breeders are essential to prevent these diseases. Read More

View Article
December 2018

Nurse telephone education for promoting a treat-to-target approach in recently diagnosed rheumatoid arthritis patients: A pilot project.

Musculoskeletal Care 2018 Dec 5. Epub 2018 Dec 5.

Larner College of Medicine, University of Vermont, Burlington, Vermont, US.

Objective: The aim of the present study was to implement a nurse telephone education programme for patients with recently diagnosed rheumatoid arthritis (RA) that promotes shared decision-making and a treat-to-target approach.

Methods: This was a pilot project of newly diagnosed adult RA patients conducted between November 2015 and December 2016. A rheumatology clinic nurse telephoned patients to offer disease education. Read More

View Article
December 2018

The Urokinase Plasminogen Activation System in Rheumatoid Arthritis: Pathophysiological Roles and Prospective Therapeutic Targets.

Curr Drug Targets 2018 Dec 4. Epub 2018 Dec 4.

School of Chemistry and Molecular Bioscience, University of Wollongong, NSW 2522. Australia.

Rheumatoid arthritis (RA) is a chronic and progressive inflammatory disease characterized in its early stages by synovial hyperplasia and inflammatory cell infiltration and later by irreversible joint tissue destruction. The plasminogen activation system (PAS) is associated with a wide range of physiological and pathophysiological states involving fibrinolysis, inflammation and tissue remodeling. Various components of the PAS are implicated in the pathophysiology of RA. Read More

View Article
December 2018

Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.

Front Immunol 2018 20;9:2696. Epub 2018 Nov 20.

Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Peptidylarginine deiminases (PAD) 2 and 4 are key enzymes in rheumatoid arthritis (RA) pathogenesis due to their ability to generate the protein targets of anti-citrullinated protein antibodies (ACPA). Anti-PAD4 antibodies that cross-react with PAD3 (anti-PAD3/4) have been identified and are associated with severe joint and lung disease. Here, we examined whether anti-PAD2 antibodies were present in patients with RA and defined their clinical significance. Read More

View Article
November 2018

Harmonisation of laboratory tests for rheumatic diseases: still a long way to go.

Ann Rheum Dis 2018 Dec 4. Epub 2018 Dec 4.

Department of Laboratory Medicine, University Hospital Gasthuisberg, Leuven, Belgium.

View Article
December 2018

Regulatory and effector B cells: Friends or foes?

J Dermatol Sci 2018 Nov 23. Epub 2018 Nov 23.

Department of Dermatology, Kanazawa University Graduate School of Medical Sciences, Kanazawa 920-8641, Japan. Electronic address:

B cells have moved to the center stage in many autoimmune diseases including autoantibody-mediated diseases and T cell-mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. B cells play an important role for immune response beyond antibody production through mechanisms like antigen presentation and cytokine production. However, not all B cells positively regulate immune responses. Read More

View Article
November 2018

Rheumatoid Arthritis Patients Achieve Better Satisfaction but Lower Functional Activities as Compared to Osteoarthritis Patients After Total Knee Arthroplasty.

J Arthroplasty 2018 Nov 15. Epub 2018 Nov 15.

Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.

Background: Recently, poor patient satisfaction after total knee arthroplasty (TKA) has gained attention mainly in osteoarthritis (OA) patients; however, satisfaction after TKA remains to be understood in rheumatoid arthritis (RA) patients. This study aimed to examine satisfaction and function after RA TKA using patient-reported outcome measures and to compare the results with those of OA-TKA.

Methods: This study enrolled 534 TKAs of 501 patients consisting of 75 TKAs of 70 RA patients and 459 TKAs of 431 OA patients. Read More

View Article
November 2018

Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study.

Arthritis Res Ther 2018 Dec 4;20(1):267. Epub 2018 Dec 4.

Joint Rheumatology Program, 1st Department of Propedeutic Internal Medicine-Rheumatology Unit, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece.

Background: Comorbidities are common in chronic systemic connective tissue diseases and are associated with adverse outcomes, increased morbidity and mortality. Although the prevalence of comorbidities has been well-studied in isolated diseases, comparative studies between different autoimmune diseases are limited. In this study, we compared the prevalence of common comorbidities between patients with systemic sclerosis (SSc) and patients with rheumatoid arthritis (RA). Read More

View Article
December 2018
2 Reads